44 results on '"Yutaka, Narita"'
Search Results
2. Regio- and diastereoselective synthesis of unsymmetrical 1,4-diketone-derived (Z)-monosilyl enol ethers via siloxyallylpotassium intermediates
- Author
-
Shuto Okuda, Yutaka Narita, Rikuo Hayashi, and Masahiro Sai
- Subjects
Materials Chemistry ,Metals and Alloys ,Ceramics and Composites ,General Chemistry ,Catalysis ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials - Abstract
This paper describes the regio- and diastereoselective synthesis of unsymmetrical 1,4-diketone-derived (Z)-monosilyl enol ethers from 1-arylallyloxysilanes and Weinreb amides using (trimethylsilyl)methylpotassium as a base.
- Published
- 2023
3. Regio- and Diastereoselective Synthesis of Unsymmetrical 1,4-Diketone-Derived (Z)-Monosilyl Enol Ethers via Siloxyallylpotassium Intermediates
- Author
-
Shuto Okuda, Yutaka Narita, Rikuo Hayashi, and Masahiro Sai
- Abstract
This paper describes the regio- and diastereoselective synthesis of unsymmetrical 1,4-diketone-derived (Z)-monosilyl enol ethers from 1-arylallyloxysilanes and Weinreb amides using (trimethylsilyl)methylpotassium as a base. The metalation of 1-arylallyloxysilanes to generate siloxyallylpotassiums is the key step in this transformation. The products can be transformed into diverse α-monofunctionalized unsymmetrical 1,4-diketones.
- Published
- 2022
4. Expression of Aldo-Keto Reductase Family 1 Member B10 in the Early Stages of Human Hepatocarcinogenesis
- Author
-
Hironori Tsuzura, Takuya Genda, Shunsuke Sato, Ayato Murata, Yoshio Kanemitsu, Yutaka Narita, Sachiko Ishikawa, Tetsu Kikuchi, Masashi Mori, Katsuharu Hirano, Katsuyori Iijima, Ryo Wada, and Takafumi Ichida
- Subjects
AKR1B10 ,HSP70 ,glypican-3 ,hepatocellular carcinoma ,chronic hepatitis ,cirrhosis ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Aldo-keto reductase family 1, member B10 (AKR1B10), a cancer-related oxidoreductase, is expressed in well-differentiated hepatocellular carcinomas (HCCs). However, AKR1B10 levels are minimal in normal liver tissues (NLs), similar to the 70-kilodalton heat shock protein (HSP70) and glypican-3. Moreover, the role of AKR1B10 in chronic hepatitis or cirrhosis, which are considered preneoplastic conditions for HCC, has not been fully elucidated. The aim of this study was to evaluate the expression of AKR1B10, HSP70, and glypican-3 in 61 HCC tissue samples compared to corresponding non-tumorous liver tissues (NTs), comprising 42 chronic hepatitis and 19 cirrhosis cases to clarify the significance of molecular changes at the preneoplastic stages of HCC. Immunohistochemical analysis demonstrated that the median expression levels of AKR1B10 were higher in HCCs than in NTs (p < 0.001) and higher in NTs than NLs (p < 0.001) with 54.8%, 2.1%, and 0.3% expression in HCCs, NTs, and NLs, respectively. HSP70 and glypican-3 were expressed in HCCs, but minimally in NTs and NLs with no significant difference between expression in NTs and NLs. Furthermore, a multivariate analysis identified an association between hepatic steatosis and AKR1B10 expression in NTs (p = 0.020). Of the three protein expressed in well-differentiated HCCs, only AKR1B10 was upregulated in preneoplastic conditions, and a steatosis-related factor might influence its expression.
- Published
- 2014
- Full Text
- View/download PDF
5. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein
- Author
-
Shunsuke Sato, Takuya Genda, Takafumi Ichida, Nozomi Amano, Sho Sato, Ayato Murata, Hironori Tsuzura, Yutaka Narita, Yoshio Kanemitsu, Katsuharu Hirano, Yuji Shimada, Katsuyori Iijima, Ryo Wada, Akihito Nagahara, and Sumio Watanabe
- Subjects
WFA+-M2BP ,hepatocellular carcinoma ,chronic hepatitis C ,risk factor ,sustained virological response ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
We aimed to clarify the association between a novel serum fibrosis marker, Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+-M2BP), and hepatocellular carcinoma (HCC) development in 355 patients with chronic hepatitis C who achieved sustained virologic response (SVR) through interferon-based antiviral therapy. Pretreatment serum WFA+-M2BP levels were quantified and the hazard ratios (HRs) for HCC development were retrospectively analyzed by Cox proportional hazard analysis. During the median follow-up time of 2.9 years, 12 patients developed HCC. Multivariate analysis demonstrated that high serum WFA+-M2BP (≥2.80 cut off index (COI), HR = 15.20, p = 0.013) and high fibrosis-4 (FIB-4) index (≥3.7, HR = 5.62, p = 0.034) were independent risk factors for HCC development. The three- and five-year cumulative incidence of HCC in patients with low WFA+-M2BP were 0.4% and 0.4%, respectively, whereas those of patients with high WFA+-M2BP were 7.7% and 17.6%, respectively (p < 0.001). In addition, combination of serum WFA+-M2BP and FIB-4 indices successfully stratified the risk of HCC: the five-year cumulative incidences of HCC were 26.9%, 6.8%, and 0.0% in patients with both, either, and none of these risk factors, respectively (p < 0.001). In conclusion, pretreatment serum WFA+-M2BP level is a useful predictor for HCC development after achieving SVR.
- Published
- 2016
- Full Text
- View/download PDF
6. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication
- Author
-
Ryo Wada, Nozomi Amano, Hironori Tsuzura, Takafumi Ichida, Katsuyori Iijima, Katsuharu Hirano, Akihito Nagahara, Sumio Watanabe, Yutaka Narita, Sho Sato, Ayato Murata, Yuji Shimada, Yoshio Kanemitsu, Takuya Genda, and Shunsuke Sato
- Subjects
Male ,Hepatocellular carcinoma ,viruses ,Hepacivirus ,Treatment outcome ,Aldo-Keto Reductases ,medicine.disease_cause ,Chronic hepatitis C ,0302 clinical medicine ,Risk Factors ,Medicine ,Aged, 80 and over ,biology ,Liver Neoplasms ,Gastroenterology ,General Medicine ,Hepatitis C ,Middle Aged ,Immunohistochemistry ,Gene Expression Regulation, Neoplastic ,Sustained virological response ,Treatment Outcome ,030220 oncology & carcinogenesis ,Human AKR1B10 protein ,030211 gastroenterology & hepatology ,Female ,Adult ,Carcinoma, Hepatocellular ,Genotype ,Hepatitis C virus ,macromolecular substances ,03 medical and health sciences ,Young Adult ,Retrospective Study ,Aldehyde Reductase ,Carcinoma ,Humans ,Risk factor ,Aged ,Retrospective Studies ,business.industry ,Hepatitis C, Chronic ,medicine.disease ,biology.organism_classification ,digestive system diseases ,Cancer research ,business - Abstract
AIM To clarify the association between aldo-keto reductase family 1 member B10 (AKR1B10) expression and hepatocarcinogenesis after hepatitis C virus eradication. METHODS In this study, we enrolled 303 chronic hepatitis C patients who had achieved sustained virological response (SVR) through interferon-based antiviral therapy. Pretreatment AKR1B10 expression in the liver was immunohistochemically assessed and quantified as a percentage of positive staining area by using image-analysis software. A multivariate Cox analysis was used to estimate the hazard ratios (HRs) of AKR1B10 expression for hepatocellular carcinoma (HCC) development after achieving SVR. The cumulative incidences of HCC development were evaluated using Kaplan-Meier analysis and the log-rank test. RESULTS Of the 303 chronic hepatitis C patients, 153 (50.5%) showed scarce hepatic AKR1B10 expression, quantified as 0%, which was similar to the expression in control normal liver tissues. However, the remaining 150 patients (49.5%) exhibited various degrees of AKR1B10 expression in the liver, with a maximal AKR1B10 expression of 73%. During the median follow-up time of 3.6 years (range 1.0-10.0 years), 8/303 patients developed HCC. Multivariate analysis revealed that only high AKR1B10 expression (≥ 8%) was an independent risk factor for HCC development (HR = 15.4, 95%CI: 1.8-132.5, P = 0.012). The 5-year cumulative incidences of HCC development were 13.7% and 0.5% in patients with high and low AKR1B10 expression, respectively (P < 0.001). During the follow-up period after viral eradication, patients expressing high levels of AKR1B10 expressed markedly higher levels of alanine aminotransferase and α-fetoprotein than did patients exhibiting low AKR1B10 expression. CONCLUSION Chronic hepatitis C patients expressing high levels of hepatic AKR1B10 had an increased risk of HCC development even after SVR.
- Published
- 2016
7. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma
- Author
-
Takuya Genda, Sachiko Ishikawa, Tetsu Kikuchi, Ayato Murata, Akihito Nagahara, Sumio Watanabe, Katsuyori Iijima, Yutaka Narita, Hironori Tsuzura, Ryo Wada, Shunsuke Sato, Masashi Mori, Yoshio Kanemitsu, Takafumi Ichida, and Katsuharu Hirano
- Subjects
medicine.medical_specialty ,Pathology ,Hepatology ,business.industry ,Hepatitis C virus ,Hazard ratio ,Gastroenterology ,Aldo-Keto Reductase Family 1 member B10 ,Reductase ,medicine.disease ,medicine.disease_cause ,Lower risk ,digestive system diseases ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Internal medicine ,Medicine ,030211 gastroenterology & hepatology ,Cumulative incidence ,Risk factor ,business - Abstract
BACKGROUND AND AIM Aldo-keto reductase family 1 member B10 (AKR1B10), a cancer-related oxidoreductase, was recently reported to be upregulated in some chronic liver diseases. However, its relevance in hepatocellular carcinoma (HCC) development is not fully assessed, especially in patients with chronic hepatitis C virus (HCV) infection. METHODS Aldo-keto reductase family 1 member B10 expression in the liver of 550 patients with chronic HCV infection was immunohistochemically assessed and quantified. A multivariate Cox model was used to estimate the hazard ratios (HRs) of AKR1B10 expression for HCC development, and the cumulative incidence of HCC was evaluated using the Kaplan-Meier method. RESULTS Aldo-keto reductase family 1 member B10 expression in the patients ranged from 0% to 80%. During the median follow-up of 3.2 years, 43 of 550 patients developed HCC. Multivariate analysis demonstrated that high AKR1B10 expression (≥6%) was an independent risk factor for HCC (HR, 6.43; 95% confidence interval, 2.90-14.25; P
- Published
- 2016
8. Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk
- Author
-
Ryo Wada, Yutaka Narita, Masashi Mori, Sachiko Ishikawa, Tetsu Kikuchi, Katsuyori Iijima, Sumio Watanabe, Yuji Shimada, Yoshio Kanemitsu, Ken Sugimoto, Hironori Tsuzura, Shunsuke Sato, Ayato Murata, Takuya Genda, Masato Kamei, Katsuharu Hirano, Akihito Nagahara, and Takafumi Ichida
- Subjects
Hepatitis B virus ,medicine.medical_specialty ,Pathology ,Hepatology ,business.industry ,Proportional hazards model ,Hazard ratio ,Reductase ,Hepatitis B ,medicine.disease_cause ,medicine.disease ,Gastroenterology ,digestive system diseases ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,030220 oncology & carcinogenesis ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Carcinoma ,030211 gastroenterology & hepatology ,Risk factor ,business - Abstract
Aim Recent reports have indicated that aldo-keto reductase family 1 member B10 (AKR1B10), a cancer-related oxidoreductase, was upregulated in some chronic liver diseases. However, few studies have reported AKR1B10 expression in chronic hepatitis B virus (HBV)-infected patients. The aim of the present study was to analyze AKR1B10 expression and its relevance on hepatocellular carcinoma (HCC) development in patients with chronic HBV infection. Methods Expression of AKR1B10 in the liver of 119 chronic HBV-infected patients was assessed and quantified immunohistochemically. A multivariate Cox model was used to estimate the hazard ratios of AKR1B10 expression for HCC development. The cumulative incidences of HCC were evaluated using Kaplan–Meier analysis. Results Expression of AKR1B10 in the study cohort ranged from 0% to 84%. During the median follow-up time (6.2 years), 13 patients developed HCC. Multivariate analysis revealed that high AKR1B10 expression (≥15%) was an independent risk factor for HCC (hazard ratio, 10.8; 95% confidence interval, 3.0–38.6; P
- Published
- 2016
9. A case of primary hepatic neuroendocrine carcinoma concomitant with biliary dilatation inside a lesion
- Author
-
Sachiko Ishikawa, Katuyori Iijima, Koichi Sato, Ryo Wada, Yoshio Kanemitsu, Ayato Murata, Akihito Nagahara, Shunsuke Sato, Yutaka Narita, Takuya Genda, Hironori Tsuzura, Tetsu Kikuchi, and Hiroshi Maekawa
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,Hepatology ,business.industry ,Bile duct ,medicine.medical_treatment ,Primary hepatic neuroendocrine carcinoma ,Lesion ,medicine.anatomical_structure ,Internal medicine ,Concomitant ,medicine ,medicine.symptom ,Hepatectomy ,business ,Biliary dilatation - Published
- 2015
10. Expression of Aldo-Keto Reductase Family 1 Member B10 in the Early Stages of Human Hepatocarcinogenesis
- Author
-
Yoshio Kanemitsu, Takafumi Ichida, Hi ronori Tsuzura, Shunsuke Sato, Tetsu Kikuchi, Yutaka Narita, Masashi Mori, Katsuyori Iijima, Ryo Wada, Ayato Murata, Takuya Genda, Sachiko Ishikawa, and Katsuharu Hirano
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Aldo-Keto Reductases ,Biology ,AKR1B10 ,HSP70 ,glypican-3 ,hepatocellular carcinoma ,chronic hepatitis ,cirrhosis ,Catalysis ,Article ,Inorganic Chemistry ,lcsh:Chemistry ,Chronic hepatitis ,Glypicans ,Aldehyde Reductase ,Internal medicine ,medicine ,Humans ,HSP70 Heat-Shock Proteins ,Physical and Theoretical Chemistry ,Molecular Biology ,lcsh:QH301-705.5 ,Spectroscopy ,Aged ,Hepatitis, Chronic ,Aged, 80 and over ,Aldo-keto reductase ,Organic Chemistry ,Liver Neoplasms ,Aldo-Keto Reductase Family 1 member B10 ,General Medicine ,Hepatology ,Middle Aged ,Immunohistochemistry ,digestive system diseases ,Computer Science Applications ,Up-Regulation ,Endocrinology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Female - Abstract
Aldo-keto reductase family 1, member B10 (AKR1B10), a cancer-related oxidoreductase, is expressed in well-differentiated hepatocellular carcinomas (HCCs). However, AKR1B10 levels are minimal in normal liver tissues (NLs), similar to the 70-kilodalton heat shock protein (HSP70) and glypican-3. Moreover, the role of AKR1B10 in chronic hepatitis or cirrhosis, which are considered preneoplastic conditions for HCC, has not been fully elucidated. The aim of this study was to evaluate the expression of AKR1B10, HSP70, and glypican-3 in 61 HCC tissue samples compared to corresponding non-tumorous liver tissues (NTs), comprising 42 chronic hepatitis and 19 cirrhosis cases to clarify the significance of molecular changes at the preneoplastic stages of HCC. Immunohistochemical analysis demonstrated that the median expression levels of AKR1B10 were higher in HCCs than in NTs (p < 0.001) and higher in NTs than NLs (p < 0.001) with 54.8%, 2.1%, and 0.3% expression in HCCs, NTs, and NLs, respectively. HSP70 and glypican-3 were expressed in HCCs, but minimally in NTs and NLs with no significant difference between expression in NTs and NLs. Furthermore, a multivariate analysis identified an association between hepatic steatosis and AKR1B10 expression in NTs (p = 0.020). Of the three protein expressed in well-differentiated HCCs, only AKR1B10 was upregulated in preneoplastic conditions, and a steatosis-related factor might influence its expression.
- Published
- 2014
11. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy
- Author
-
Tetsu Kikuchi, Sachiko Ishikawa, Yutaka Narita, Katsuyori Iijima, Takuya Genda, Shunsuke Sato, Hironori Tsuzura, Ryo Wada, Takafumi Ichida, Katsuharu Hirano, and Yoshio Kanemitsu
- Subjects
medicine.medical_specialty ,Multivariate analysis ,Hepatology ,business.industry ,Incidence (epidemiology) ,Hazard ratio ,Gastroenterology ,medicine.disease ,digestive system diseases ,Surgery ,Interferon ,Internal medicine ,Hepatocellular carcinoma ,Cohort ,medicine ,Cumulative incidence ,Risk factor ,business ,medicine.drug - Abstract
Background and Aim The purpose of this study was to evaluate the usefulness of liver stiffness measurement (LSM) for assessing the risk of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients receiving interferon (IFN) therapy. Methods One hundred fifty-one CHC patients who underwent LSM and received IFN therapy were included in the estimation cohort, and 56 were included in the validation study. The cumulative HCC incidences were evaluated using Kaplan–Meier plot analysis and the log-rank test. Multivariate Cox proportional hazard analyses were used to estimate the hazard ratios (HRs) of variables for HCC. Results In the estimation cohort, 9 of 151 patients developed HCC during the median follow-up time of 722 days. Multivariate analysis identified three independent risk factors for HCC: LSM (≥ 14.0 kPa, HR 5.58, P = 0.020), platelet count (
- Published
- 2013
12. Association of Visceral Obesity with High Viral Load and Histological Findings in Elderly Patients with Genotype 1 Chronic Hepatitis C
- Author
-
Katsuyori Iijima, Shunsuke Sato, Katsuharu Hirano, Takafumi Ichida, Yoshio Kanemitsu, Yutaka Narita, Tetsu Kikuchi, Ryo Wada, Hironori Tsuzura, and Takuya Genda
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Genotype ,Adipokine ,Comorbidity ,Hepacivirus ,Severity of Illness Index ,Gastroenterology ,Insulin resistance ,Adipokines ,Internal medicine ,Prevalence ,Internal Medicine ,medicine ,Humans ,Prospective Studies ,Aged ,Retrospective Studies ,Aged, 80 and over ,Adiponectin ,business.industry ,Leptin ,Age Factors ,General Medicine ,Hepatitis C, Chronic ,Middle Aged ,Viral Load ,medicine.disease ,Obesity, Abdominal ,Multivariate Analysis ,Female ,Steatosis ,Metabolic syndrome ,Tomography, X-Ray Computed ,business ,Viral load ,Dyslipidemia - Abstract
OBJECTIVE Genotype 1 chronic hepatitis C (G1CHC) is generally accompanied by metabolic disturbances related to visceral obesity, such as insulin resistance, steatosis, or dyslipidemia. Because these abnormalities negatively influence the clinical course of G1CHC, we sought to clarify the effect of visceral obesity on the pathophysiology of G1CHC. METHODS We evaluated 180G1CHC patients for the presence of visceral obesity on the basis of computed tomography findings. Multivariate analysis was performed to estimate the relationship between visceral obesity and demographic, viral, and biochemical characteristics of patients. The associations of visceral obesity with histological findings and serum adipokine levels were also analyzed. RESULTS Multiple logistic regression analysis revealed that visceral obesity was independently associated with metabolic syndrome, platelet count, high-density lipoprotein level, and serum viral load in elderly patients (≥65 years). Multiple linear regression analysis confirmed the association between visceral obesity and high viral load. However, visceral obesity was not correlated with viral load in non-elderly patients (
- Published
- 2013
13. Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk
- Author
-
Masashi, Mori, Takuya, Genda, Takafumi, Ichida, Ayato, Murata, Masato, Kamei, Hironori, Tsuzura, Shunsuke, Sato, Yutaka, Narita, Yoshio, Kanemitsu, Sachiko, Ishikawa, Tetsu, Kikuchi, Yuji, Shimada, Katsuharu, Hirano, Katsuyori, Iijima, Ken, Sugimoto, Ryo, Wada, Akihito, Nagahara, and Sumio, Watanabe
- Abstract
Recent reports have indicated that aldo-keto reductase family 1 member B10 (AKR1B10), a cancer-related oxidoreductase, was upregulated in some chronic liver diseases. However, few studies have reported AKR1B10 expression in chronic hepatitis B virus (HBV)-infected patients. The aim of the present study was to analyze AKR1B10 expression and its relevance on hepatocellular carcinoma (HCC) development in patients with chronic HBV infection.Expression of AKR1B10 in the liver of 119 chronic HBV-infected patients was assessed and quantified immunohistochemically. A multivariate Cox model was used to estimate the hazard ratios of AKR1B10 expression for HCC development. The cumulative incidences of HCC were evaluated using Kaplan-Meier analysis.Expression of AKR1B10 in the study cohort ranged from 0% to 84%. During the median follow-up time (6.2 years), 13 patients developed HCC. Multivariate analysis revealed that high AKR1B10 expression (≥15%) was an independent risk factor for HCC (hazard ratio, 10.8; 95% confidence interval, 3.0-38.6; P 0.001). The 5-year cumulative incidences of HCC were 20.6% and 2.6% in patients with high and low AKR1B10 expression, respectively (P 0.001). Patients with high AKR1B10 expression had significantly higher alanine aminotransferase levels during follow-up than those with low expression, even though antiviral treatment decreased HBV-DNA levels in both groups.Chronic HBV-infected patients with high hepatic AKR1B10 expression had an increased risk of HCC development. This suggests that AKR1B10 upregulation might play a role in the early stages of HBV-related hepatocarcinogenesis.
- Published
- 2016
14. Up‐regulated aldo‐keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha‐fetoprotein and hepatocellular carcinoma
- Author
-
Hironori Tsuzura, Takuya Genda, Yoshio Kanemitsu, Tetsu Kikuchi, Katsuyori Iijima, Katsuharu Hirano, Yutaka Narita, Ryo Wada, Shunsuke Sato, and Takafumi Ichida
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Carcinoma, Hepatocellular ,Cirrhosis ,Hepatitis C virus ,Aldo-Keto Reductases ,liver ,Chronic liver disease ,medicine.disease_cause ,Gastroenterology ,Gene Expression Regulation, Enzymologic ,alpha-fetoprotein ,AKR1B10 ,Aldehyde Reductase ,Risk Factors ,Internal medicine ,Clinical Studies ,Biomarkers, Tumor ,medicine ,chronic hepatitis C ,Humans ,neoplasms ,Aged ,Oligonucleotide Array Sequence Analysis ,Hepatology ,business.industry ,Gene Expression Profiling ,Liver Neoplasms ,Cancer ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Immunohistochemistry ,digestive system diseases ,Up-Regulation ,risk factor ,Case-Control Studies ,Hepatocellular carcinoma ,Female ,alpha-Fetoproteins ,Alpha-fetoprotein ,Viral hepatitis ,business ,carcinogenesis ,microarray - Abstract
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related death worldwide 1. Approximately 70–90% of patients with HCC have an established background of chronic liver disease and cirrhosis 1. Persistent infection with the hepatitis C virus (HCV) is one of the major causes of chronic liver disease leading to the development of HCC. Persistent HCV infection is responsible for 27–75% of the HCC cases in Europe and the United States and >80% of the HCC cases in Japan 2, 3. The annual incidence of HCC development is 2–8% in cirrhotic patients with chronic HCV infection 4, 5. Persons with anti-HCV positivity were shown to have a 20-fold increased risk of developing HCC in comparison with those who were negative for anti-HCV 6. Thus, the carcinogenic role of persistent HCV infection appears to be significant. However, the molecular mechanism of HCV-related hepatocarcinogenesis is not completely understood, particularly in its early stages. Alpha-fetoprotein (AFP) is the most thoroughly characterized carcinofetal gene product and its usefulness in the surveillance and diagnosis of HCC is well established. On the other hand, AFP elevation is recognized not only in patients with HCC but also in patients with chronic viral hepatitis or cirrhosis, who have no evidence of HCC. AFP elevation was observed in over 15% of patients with chronic hepatitis C in the absence of HCC 7. In addition, several studies have indicated that AFP elevation is a significant predictor of HCC development 8–10. Recent reports reveal that the estimated HCC risk in patients with elevated AFP is over three-fold higher than that in patients with normal AFP 11, 12. These observations suggest that the molecular alterations associated with the very early stages of hepatocarcinogenesis have occurred in the livers of patients with chronic hepatitis C with AFP elevation. In this study, we attempted to identify a specific gene expression signature by performing microarray analysis on the livers of patients with chronic hepatitis C and AFP elevation, which is considered high risk for development of HCC.
- Published
- 2012
15. Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma
- Author
-
Shunsuke, Sato, Takuya, Genda, Takafumi, Ichida, Ayato, Murata, Hironori, Tsuzura, Yutaka, Narita, Yoshio, Kanemitsu, Sachiko, Ishikawa, Tetsu, Kikuchi, Masashi, Mori, Katsuharu, Hirano, Katsuyori, Iijima, Ryo, Wada, Akihito, Nagahara, and Sumio, Watanabe
- Subjects
Adult ,Aged, 80 and over ,Risk ,Carcinoma, Hepatocellular ,Incidence ,Liver Neoplasms ,Aldo-Keto Reductases ,Gene Expression ,Kaplan-Meier Estimate ,Hepatitis C, Chronic ,Middle Aged ,Immunohistochemistry ,Up-Regulation ,Liver ,Aldehyde Reductase ,Predictive Value of Tests ,Humans ,Aged ,Proportional Hazards Models - Abstract
Aldo-keto reductase family 1 member B10 (AKR1B10), a cancer-related oxidoreductase, was recently reported to be upregulated in some chronic liver diseases. However, its relevance in hepatocellular carcinoma (HCC) development is not fully assessed, especially in patients with chronic hepatitis C virus (HCV) infection.Aldo-keto reductase family 1 member B10 expression in the liver of 550 patients with chronic HCV infection was immunohistochemically assessed and quantified. A multivariate Cox model was used to estimate the hazard ratios (HRs) of AKR1B10 expression for HCC development, and the cumulative incidence of HCC was evaluated using the Kaplan-Meier method.Aldo-keto reductase family 1 member B10 expression in the patients ranged from 0% to 80%. During the median follow-up of 3.2 years, 43 of 550 patients developed HCC. Multivariate analysis demonstrated that high AKR1B10 expression (≥6%) was an independent risk factor for HCC (HR, 6.43; 95% confidence interval, 2.90-14.25; P 0.001). The 5-year cumulative incidences of HCC were 22.8% and 2.2% in patients with high and low AKR1B10 expression, respectively (P 0.001). In subgroup analyses, the effects of high AKR1B10 expression on HCC development risk were significant over strata. In particular, HRs attributed to high AKR1B10 expression were significant in the subgroups that had been considered at a lower risk of HCC, such as in patients with younger age and mild hepatic fibrosis or those who achieved sustained virological response after interferon therapy.Various degrees of AKR1B10 upregulation in the liver were observed in patients with chronic HCV infection, and high AKR1B10 expression could be a novel predictor of HCC.
- Published
- 2015
16. Transient elastography-derived liver stiffness measurements were found to be useful for predicting liver infiltration in a case of mature T-cell neoplasm involving liver dysfunction
- Author
-
Kunimoto, Ichikawa, Yutaka, Narita, Yasunori, Ota, Norio, Komatsu, and Michiaki, Koike
- Subjects
Male ,Biopsy ,Prednisolone ,T-Lymphocytes ,Case Report ,Liver Function Tests ,Predictive Value of Tests ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Neoplasm Invasiveness ,Cyclophosphamide ,Aged ,Cell Proliferation ,Remission Induction ,Bone Marrow Examination ,Immunohistochemistry ,Elasticity ,Treatment Outcome ,Liver ,Doxorubicin ,Vincristine ,Positron-Emission Tomography ,Elasticity Imaging Techniques ,Tomography, X-Ray Computed - Abstract
Transient elastography (TE) is a novel, non-invasive imaging technique for measuring liver stiffness (LS). It is considered to be useful for predicting the severity of fibrosis and the risk of cirrhosis or hepatocellular carcinoma. However, the association between the presence of diffuse regions of increased cell density in the liver and elevated LS values has not been assessed. We experienced a case in which a mature T-cell neoplasm had invaded the liver, but the infiltrating lesion was not detected by contrast-enhanced computed tomography (CT) or fluorodeoxyglucose positron emission tomography/CT scans. Instead, the tumor’s presence was indicated by the change in the patient’s TE-derived LS values after chemotherapy. At diagnosis liver dysfunction was detected in a biochemical examination, and mean LS value was as high as 25.4 kPa [interquartile range (IQR): 0.3, success rate (SR):100%]. After chemotherapy, the patient’s mean LS value fell to 4.3 kPa (IQR: 0.8, SR:100%). A follow-up pathological investigation demonstrated that proliferating abnormal T-cells were no longer present in the patient’s liver. This is the first report to describe the use of LS data to support a diagnosis of liver infiltration by tumor cells exhibiting a portal and sinusoidal distribution pattern rather than a focal pattern. Elevated TE-derived LS values should lead to hepatic tumor infiltration being considered during initial examinations or a suspicion of recurrence during follow-up examination of lymphoma patients who achieve complete remission, even when radiological investigations do not detect abnormalities in the liver.
- Published
- 2015
17. Mo1265 Significance of atrophic Changes of Gastric Mucosa in Patients With Gastric Mucosal Injury in Low-Dose Aspirin Users
- Author
-
Akihito Nagahara, Mariko Hojo, Yuji Shimada, Katsuyori Iijima, Yutaka Narita, Daisuke Asaoka, Sumio Watanabe, Hironori Tuzura, Kentaro Izumi, Takuya Genda, Shunsuke Sato, Ayato Murata, Yoshio Kanemitsu, and Masato Kamei
- Subjects
medicine.medical_specialty ,medicine.anatomical_structure ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Gastric mucosa ,In patient ,business ,Low dose aspirin - Published
- 2016
18. Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein
- Author
-
Ryo Wada, Yuji Shimada, Nozomi Amano, Yutaka Narita, Akihito Nagahara, Katsuyori Iijima, Shunsuke Sato, Takuya Genda, Takafumi Ichida, Sumio Watanabe, Sho Sato, Ayato Murata, Katsuharu Hirano, Hironori Tsuzura, and Yoshio Kanemitsu
- Subjects
Male ,Receptors, N-Acetylglucosamine ,Hepacivirus ,medicine.disease_cause ,Gastroenterology ,Polyethylene Glycols ,lcsh:Chemistry ,0302 clinical medicine ,Risk Factors ,WFA+-M2BP ,hepatocellular carcinoma ,chronic hepatitis C ,risk factor ,sustained virological response ,Fibrosis ,Interferon ,Cumulative incidence ,lcsh:QH301-705.5 ,Spectroscopy ,Aged, 80 and over ,Membrane Glycoproteins ,biology ,Liver Neoplasms ,Hazard ratio ,General Medicine ,Middle Aged ,Wisteria floribunda ,Recombinant Proteins ,Computer Science Applications ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Plant Lectins ,Mac 2 binding protein ,Protein Binding ,medicine.drug ,Adult ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Hepatitis C virus ,Article ,Catalysis ,Inorganic Chemistry ,Young Adult ,03 medical and health sciences ,Antigens, Neoplasm ,Internal medicine ,Ribavirin ,medicine ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Aged ,Retrospective Studies ,business.industry ,Organic Chemistry ,Interferon-alpha ,Hepatitis C, Chronic ,biology.organism_classification ,medicine.disease ,digestive system diseases ,lcsh:Biology (General) ,lcsh:QD1-999 ,Immunology ,business - Abstract
We aimed to clarify the association between a novel serum fibrosis marker, Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+-M2BP), and hepatocellular carcinoma (HCC) development in 355 patients with chronic hepatitis C who achieved sustained virologic response (SVR) through interferon-based antiviral therapy. Pretreatment serum WFA+-M2BP levels were quantified and the hazard ratios (HRs) for HCC development were retrospectively analyzed by Cox proportional hazard analysis. During the median follow-up time of 2.9 years, 12 patients developed HCC. Multivariate analysis demonstrated that high serum WFA+-M2BP (≥2.80 cut off index (COI), HR = 15.20, p = 0.013) and high fibrosis-4 (FIB-4) index (≥3.7, HR = 5.62, p = 0.034) were independent risk factors for HCC development. The three- and five-year cumulative incidence of HCC in patients with low WFA+-M2BP were 0.4% and 0.4%, respectively, whereas those of patients with high WFA+-M2BP were 7.7% and 17.6%, respectively (p < 0.001). In addition, combination of serum WFA+-M2BP and FIB-4 indices successfully stratified the risk of HCC: the five-year cumulative incidences of HCC were 26.9%, 6.8%, and 0.0% in patients with both, either, and none of these risk factors, respectively (p < 0.001). In conclusion, pretreatment serum WFA+-M2BP level is a useful predictor for HCC development after achieving SVR.
- Published
- 2016
19. Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy
- Author
-
Yutaka, Narita, Takuya, Genda, Hironori, Tsuzura, Shunsuke, Sato, Yoshio, Kanemitsu, Sachiko, Ishikawa, Tetsu, Kikuchi, Katsuharu, Hirano, Katsuyori, Iijima, Ryo, Wada, and Takafumi, Ichida
- Subjects
Adult ,Aged, 80 and over ,Male ,Carcinoma, Hepatocellular ,Liver Neoplasms ,Interferon-alpha ,Hepatitis C, Chronic ,Interferon alpha-2 ,Middle Aged ,Antiviral Agents ,Recombinant Proteins ,Young Adult ,Liver ,Predictive Value of Tests ,Ribavirin ,Elasticity Imaging Techniques ,Humans ,Female ,Aged ,Forecasting - Abstract
The purpose of this study was to evaluate the usefulness of liver stiffness measurement (LSM) for assessing the risk of hepatocellular carcinoma (HCC) in chronic hepatitis C (CHC) patients receiving interferon (IFN) therapy.One hundred fifty-one CHC patients who underwent LSM and received IFN therapy were included in the estimation cohort, and 56 were included in the validation study. The cumulative HCC incidences were evaluated using Kaplan-Meier plot analysis and the log-rank test. Multivariate Cox proportional hazard analyses were used to estimate the hazard ratios (HRs) of variables for HCC.In the estimation cohort, 9 of 151 patients developed HCC during the median follow-up time of 722 days. Multivariate analysis identified three independent risk factors for HCC: LSM (≥ 14.0 kPa, HR 5.58, P = 0.020), platelet count ( 14.1 × 10(4) /μL, HR 5.59, P = 0.034), and non-sustained virological response (HR 8.28, P = 0.049). The cumulative incidence of HCC development at 3 years was 59.6%, 8.2%, and 0.0% in patients with all three risk factors, one to two risk factors, and none of these risk factors, respectively. The incidence of HCC was significantly different between these groups (P 0.001). In the validation cohort, HCC incidence was also significantly different with respect to these risk factors (P = 0.037).LSM, platelet count, and IFN-therapeutic effect could be used to successfully stratify the risk of HCC in patients receiving IFN therapy and demonstrate the usefulness of LSM before IFN therapy for the management of CHC patients.
- Published
- 2013
20. Mo1258 Impact of Gender Differences in Prevalence of Upper Gastrointestinal Mucosal Injuries - Esophagus, Stomach, Duodenam
- Author
-
Takuya Genda, Sumio Watanabe, Yutaka Narita, Yuji Shimada, Ayato Murata, Masato Kamei, Katsuyori Iijima, Shunsuke Sato, Yoshio Kanemitsu, Mariko Hojo, Hironori Tuzura, Daisuke Asaoka, Akihito Nagahara, and Kentaro Izumi
- Subjects
Esophagus stomach ,medicine.medical_specialty ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Upper gastrointestinal ,business - Published
- 2016
21. Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C
- Author
-
Hironori Tsuzura, Katsuyori Ijima, Yoshio Kanemitsu, Tetsu Kikuchi, Yutaka Narita, Takuya Genda, Takafumi Ichida, Katsuharu Hirano, and Shunsuke Sato
- Subjects
medicine.medical_specialty ,Univariate analysis ,Hepatology ,Triglyceride ,business.industry ,Hepatitis C virus ,medicine.disease_cause ,chemistry.chemical_compound ,chemistry ,Interferon ,Internal medicine ,Immunology ,Genotype ,Medicine ,business ,Viral load ,Lipoprotein ,medicine.drug - Abstract
The serum hepatitis C virus (HCV) load is persistently stable in patients with untreated chronic hepatitis C, but its differences between individuals vary widely (above 4 logU/mL). Because serum viral load is an important factor for predicting clinical outcome of interferon-based antiviral therapy, this study was performed to clarify the factors associated with serum viral load in chronic hepatitis C patients. We retrospectively analyzed data from 669 chronic hepatitis C patients with HCV genotype 1 or 2 infection. Stepwise regression analysis was used to estimate the relationship between demographic, viral, or biochemical variables and serum viral load. In univariate analysis, serum lipid profiles, such as total cholesterol, low-density lipoprotein (LDL) and triglyceride levels, and hemoglobin A1c (HbA1c) were correlated with the serum HCV viral load. In multivariate analysis, HCV genotype 1 infection and higher total cholesterol levels were associated with higher viral load. After stratification by HCV genotype, the serum viral load was associated with triglyceride and HbA1c in genotype 1 and with platelet counts and LDL in genotype 2. Histological data (413 patients) showed correlation between severe liver fibrosis and decreased serum viral load in patients with HCV genotype 2 but not genotype 1 infection. These results suggest that viral kinetics is affected by different host factors for genotypes 1 and 2.
- Published
- 2010
22. [Untitled]
- Author
-
Shiro Kobayashi, Hiroshi Uyama, and Yutaka Narita
- Subjects
Dispersion polymerization ,Living free-radical polymerization ,chemistry.chemical_compound ,Polymerization ,Chemistry ,Polymer chemistry ,Cationic polymerization ,Reversible addition−fragmentation chain-transfer polymerization ,Oxazoline ,Macromonomer ,Ring-opening polymerization - Published
- 1992
23. Novel multifunctional initiators for polymerization of 2-oxazolines
- Author
-
Hiroshi Uyama, Junichi Ishiyama, Shiro Kobayashi, and Yutaka Narita
- Subjects
Polymers and Plastics ,Organic Chemistry ,Cationic polymerization ,Solution polymerization ,Degree of polymerization ,Ring-opening polymerization ,Inorganic Chemistry ,chemistry.chemical_compound ,Monomer ,chemistry ,Polymerization ,Polymer chemistry ,Materials Chemistry ,Xylylene ,Bifunctional - Abstract
Polymerization of 2-oxazolines was carried out using bifunctional and tetrafunctional initiators. Allyl-type dihalides and xylylene dihalides were used as bifunctional initiators. The allyl-type dihalides employed are 1,4-dibromo-2-butene and 3-iodo-2-(iodomethyl)-1-propene and the xylylene dihalides are p-xylylene diiodies and p-, m-, and o-xylylene dibromides. The degree of polymerization (DP) of the resulting polymer was very close to the feed ratio of the monomer to initiator. From a kinetic study, it was found that the polymerization using these bifunctional initiator for 2-oxazoline in a fast initiation-slow propagation system
- Published
- 1992
24. Novel Initiators Having Acetylene Group for Polymerization of 2-Oxazolines
- Author
-
Toshild Mori, Shiro Kobayashi, Yutaka Narita, and Hiroshi Uyama
- Subjects
chemistry.chemical_compound ,Chain-growth polymerization ,Polymerization ,Chemistry ,Bromide ,Polymer chemistry ,Cationic polymerization ,Organic chemistry ,Chain transfer ,Reversible addition−fragmentation chain-transfer polymerization ,General Chemistry ,Ionic polymerization ,Ring-opening polymerization - Abstract
Propagylic halide type compounds such as propagyl bromide, 1,4-dibromo-2-butyne, and 1,6-dibromo-2,4-hexadiyne, were used for the polymerization of 2-oxazolines. The polymerization initiated by the...
- Published
- 1991
25. Synthesis of Poly(2-oxazoline) Ionene Polymer
- Author
-
Hiroshi Uyama, Shiro Kobayashi, and Yutaka Narita
- Subjects
chemistry.chemical_classification ,Aqueous solution ,Polymers and Plastics ,Chemistry ,Cationic polymerization ,Oxazoline ,Polymer ,Ring-opening polymerization ,Polyelectrolyte ,chemistry.chemical_compound ,Diamine ,Polymer chemistry ,Materials Chemistry ,Living polymerization - Abstract
Preparation des ionenes par polymerisation cationique de la 2-methyl-2-oxazoline puis polyaddition avec une diamine (TMEDA, DABCO, bipyridine) de la poly(N-acetylethyleneimine) vivante obtenue. Etude du comportement viscosimetrique de ces polymeres en solution aqueuse
- Published
- 1990
26. [Clinical significance of recurrence of hepatitis C virus after liver transplantation--Japanese experience--]
- Author
-
Takafumi, Ichida, Hiroki, Mori, Tetsu, Kikuchi, Satoshi, Abe, Masakuni, Ishikawa, Romi, Murakami, Yutaka, Narita, and Kaoru, Ogawa
- Subjects
Age Factors ,Hepacivirus ,Interferon-beta ,Prognosis ,Hepatitis C ,Tissue Donors ,Liver Transplantation ,Europe ,Survival Rate ,Postoperative Complications ,Japan ,Secondary Prevention ,Humans ,RNA, Viral - Published
- 2006
27. 20412 Assessment of Heat Resistant Sprayed Coating for High Temperature Components
- Author
-
Masanobu Nakamura, Tomohiro Sugimoto, Keiji Sonoya, Hiroaki Takanami, and Yutaka Narita
- Subjects
Heat resistant ,Materials science ,Coating ,engineering ,engineering.material ,Composite material - Published
- 2013
28. 454 Development of heat-resistant thermal spray technology in semiconductor manufacturing equipment
- Author
-
Keiji Sonoya, Masanobu Nakamura, Hiroaki Takanami, and Yutaka Narita
- Subjects
Heat resistant ,Engineering ,business.industry ,Semiconductor device fabrication ,Process engineering ,business ,Thermal spraying - Published
- 2012
29. Model for end-stage liver disease (MELD) score and cost-effectiveness on living donor liver transplantation
- Author
-
Takafumi Ichida, Romi Murakami, and Yutaka Narita
- Subjects
medicine.medical_specialty ,Cost effectiveness ,business.industry ,Gastroenterology ,Hepatology ,Colorectal surgery ,Surgery ,Model for End-Stage Liver Disease ,Surgical oncology ,Internal medicine ,medicine ,Living donor liver transplantation ,business ,Abdominal surgery - Published
- 2006
30. A study of the effects of saliva stimulation by nizatidine on dry mouth symptoms of primary biliary cirrhosis
- Author
-
Tetsu Kikuchi, Takafumi Ichida, Hironori Tsuzura, Shunsuke Sato, Yutaka Narita, Katsuharu Hirano, Katsuyori Iijima, Yoshio Kanemitsu, and Takuya Genda
- Subjects
medicine.medical_specialty ,Saliva ,Hepatology ,Visual analogue scale ,business.industry ,Stimulation ,medicine.disease ,Dry mouth ,digestive system ,Gastroenterology ,digestive system diseases ,Surgery ,stomatognathic diseases ,fluids and secretions ,Primary biliary cirrhosis ,stomatognathic system ,Internal medicine ,Sicca syndrome ,medicine ,Original Article ,medicine.symptom ,skin and connective tissue diseases ,business ,Nizatidine ,medicine.drug - Abstract
To elucidate the effect of saliva stimulation by nizatidine on oral symptoms of primary biliary cirrhosis (PBC) by administering it to PBC cases.From among 73 cases that had been definitively diagnosed as PBC at our hospital by February 2010, we selected 27 cases of PBC, 4 males and 23 females, as subjects. We obtained subjects' consent after giving them a full explanation of the administration of nizatidine. Nizatidine 150 mg was administered internally twice daily, after morning and evening meals. To observe changes in the quantity of saliva secreted, chewing gum tests were carried out four times: before the initial dose, and after 6 mo, 12 mo and 24 mo of administration. For subjective dry mouth symptoms, a visual analog scale (VAS) method was used to assess their feelings of oral dryness and eating difficulty, five times: before the initial dose, and after 1, 6, 12 and 24 mo of administration in 8 cases. The nutritional condition and the hepatic functional reserve were compared between before and after the nizatidine treatment.The result of a chewing gum test on the subjects before the administration of nizatidine showed that 50% produced less than 10 mL of saliva, i.e., the standard under which cases are considered to have hyposalivation. The results of these tests showed that the quantity of saliva secreted was 10.5 ± 6.8 mL before administration of nizatidine, 10.9 ± 6.0 mL after 6 mo, 10.6 ± 4.9 mL after 12 mo, and 11.8 ± 6.8 mL after 24 mo administration. Thus, there was a slowly increasing trend in the quantity of saliva in the whole group. The percentage of subjects with saliva production above 10 mL was 45.8% after 6 mo administration of nizatidine, that is, only a slight change from before its administration, but it was 64.3% after 12 mo, that is, a significant increase. The saliva secretion by subject patients was examined before the beginning of administration of nizatidine, 12 mo later, and 24 mo later, and Fisher's combined probability test was used to examine the results for increases in saliva secretion. The analysis yielded P values of 0.51 and 0.53 for 12 mo later and 24 mo later, respectively. Thus, although there was no statistically significant increase, it was confirmed that saliva secretion tended to increase. A VAS method was employed to study the intensities of subjective symptoms of oral dryness and eating difficulty. Almost every case indicated some improvement of subjective oral dryness on the VAS early in the administration, i.e., one month after. We also studied the effects of the administration of nizatidine on nutritional condition, hepatic functional reserve, and long-term prognosis of PBC. No significant improvements in cholinesterase (ChE) level, albumin (Alb) level, or Child-Pugh score were found during the period of observation from the beginning to the end of administration of nizatidine, nor in comparison with the non-administration group. A comparative analysis between before administration and 24 mo later yielded P values of 0.41 for Alb, 0.56 for ChE, and 0.59 for the Child-Pugh scores.It was confirmed that administering nizatidine to cases of PBC with dry mouth increased the secretion of saliva and improved the symptoms.
- Published
- 2013
31. Novel bifunctional initiator for polymerization of 2-oxazolines via fast initiation
- Author
-
Shiro Kobayashi, Yutaka Narita, and Hiroshi Uyama
- Subjects
Inorganic Chemistry ,chemistry.chemical_compound ,Polymers and Plastics ,Polymerization ,chemistry ,Organic Chemistry ,Kinetics ,Polymer chemistry ,Materials Chemistry ,Cationic polymerization ,Bifunctional ,Ring-opening polymerization - Abstract
Les composes CH 2 X−CH=CH−CH 2 X (X=Cl, Br) et CH 2 =C(CH 2 X) CH 2 X (X=I, Cl) sont des amorceurs d'initiation rapide et de propagation lente de la polymerisation cationique d'alkyl-2 oxazolines-2
- Published
- 1990
32. Studies on the Quality of Sliver and Yarn
- Author
-
Yutaka Narita and Kazuo Mihira
- Subjects
General Medicine - Published
- 1951
33. Studies on the Quality of Sliver and Yarn (V)
- Author
-
Hosaku Uchida, Kazuo Mihira, and Yutaka Narita
- Subjects
General Medicine - Published
- 1952
34. Studies on the Quality of Sliver and Yarn (IV)
- Author
-
Hosaku Uchida, Kazuo Mihira, and Yutaka Narita
- Subjects
General Medicine - Published
- 1952
35. Studies on the Quality of Sliver and Yarn, III
- Author
-
Hosaku Uchida, Yutaka Narita, Kazuo Mihira, and Shigemitsu Nobuhara
- Subjects
visual_art ,media_common.quotation_subject ,visual_art.visual_art_medium ,Quality (business) ,General Medicine ,Agricultural engineering ,Yarn ,Mathematics ,media_common - Published
- 1951
36. A Study on the Quality of Sliver and Yarn
- Author
-
Kazuo Mihira, Yutaka Narita, and Hosaku Uchida
- Subjects
visual_art ,media_common.quotation_subject ,visual_art.visual_art_medium ,Quality (business) ,General Medicine ,Agricultural engineering ,Yarn ,media_common ,Mathematics - Published
- 1951
37. A Note on the 'Theory of Draft'
- Author
-
Yutaka Narita
- Subjects
Engineering ,business.industry ,Law ,General Medicine ,business - Published
- 1951
38. Theory of doubliug
- Author
-
Yutaka Narita
- Subjects
Physics ,Theoretical physics ,General Medicine ,Relationship between string theory and quantum field theory ,Abstract model theory - Published
- 1948
39. Estimate of the breaking streugth of bundle yarns
- Author
-
Yutaka Narita
- Subjects
Bundle ,Geometry ,General Medicine ,Mathematics - Published
- 1948
40. The Effect of Doubling and Drafting on the Properties of Evenness of Sliver and Yarn
- Author
-
Yutaka Narita, Kazuo Mihira, and Hosaku Uchida
- Subjects
visual_art ,visual_art.visual_art_medium ,Species evenness ,General Medicine ,Yarn ,Composite material ,Mathematics - Published
- 1951
41. Estimate of the strength of bundle yarns
- Author
-
Yutaka Narita
- Subjects
Bundle ,General Medicine ,Composite material ,Mathematics - Published
- 1947
42. Influence of the Drafting Irregularity on the Doubling Dffects
- Author
-
Hosaku Uchida, Kazuo Mihira, and Yutaka Narita
- Subjects
General Medicine - Published
- 1952
43. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
- Author
-
Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, Hirano K, Iijima K, Wada R, Nagahara A, and Watanabe S
- Subjects
- Adult, Aged, Aged, 80 and over, Aldo-Keto Reductases, Carcinoma, Hepatocellular therapy, Female, Genotype, Hepacivirus, Hepatitis C, Chronic complications, Humans, Immunohistochemistry, Liver Neoplasms therapy, Male, Middle Aged, Retrospective Studies, Risk Factors, Treatment Outcome, Young Adult, Aldehyde Reductase metabolism, Carcinoma, Hepatocellular metabolism, Gene Expression Regulation, Neoplastic, Hepatitis C, Chronic metabolism, Liver Neoplasms metabolism
- Abstract
Aim: To clarify the association between aldo-keto reductase family 1 member B10 (AKR1B10) expression and hepatocarcinogenesis after hepatitis C virus eradication., Methods: In this study, we enrolled 303 chronic hepatitis C patients who had achieved sustained virological response (SVR) through interferon-based antiviral therapy. Pretreatment AKR1B10 expression in the liver was immunohistochemically assessed and quantified as a percentage of positive staining area by using image-analysis software. A multivariate Cox analysis was used to estimate the hazard ratios (HRs) of AKR1B10 expression for hepatocellular carcinoma (HCC) development after achieving SVR. The cumulative incidences of HCC development were evaluated using Kaplan-Meier analysis and the log-rank test., Results: Of the 303 chronic hepatitis C patients, 153 (50.5%) showed scarce hepatic AKR1B10 expression, quantified as 0%, which was similar to the expression in control normal liver tissues. However, the remaining 150 patients (49.5%) exhibited various degrees of AKR1B10 expression in the liver, with a maximal AKR1B10 expression of 73%. During the median follow-up time of 3.6 years (range 1.0-10.0 years), 8/303 patients developed HCC. Multivariate analysis revealed that only high AKR1B10 expression (≥ 8%) was an independent risk factor for HCC development (HR = 15.4, 95%CI: 1.8-132.5, P = 0.012). The 5-year cumulative incidences of HCC development were 13.7% and 0.5% in patients with high and low AKR1B10 expression, respectively (P < 0.001). During the follow-up period after viral eradication, patients expressing high levels of AKR1B10 expressed markedly higher levels of alanine aminotransferase and α-fetoprotein than did patients exhibiting low AKR1B10 expression., Conclusion: Chronic hepatitis C patients expressing high levels of hepatic AKR1B10 had an increased risk of HCC development even after SVR., Competing Interests: Conflict-of-interest statement: The authors declare no conflict of interest related to this study.
- Published
- 2016
- Full Text
- View/download PDF
44. A study of the effects of saliva stimulation by nizatidine on dry mouth symptoms of primary biliary cirrhosis.
- Author
-
Kikuchi T, Hirano K, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Narita Y, Iijima K, and Ichida T
- Abstract
Aim: To elucidate the effect of saliva stimulation by nizatidine on oral symptoms of primary biliary cirrhosis (PBC) by administering it to PBC cases., Methods: From among 73 cases that had been definitively diagnosed as PBC at our hospital by February 2010, we selected 27 cases of PBC, 4 males and 23 females, as subjects. We obtained subjects' consent after giving them a full explanation of the administration of nizatidine. Nizatidine 150 mg was administered internally twice daily, after morning and evening meals. To observe changes in the quantity of saliva secreted, chewing gum tests were carried out four times: before the initial dose, and after 6 mo, 12 mo and 24 mo of administration. For subjective dry mouth symptoms, a visual analog scale (VAS) method was used to assess their feelings of oral dryness and eating difficulty, five times: before the initial dose, and after 1, 6, 12 and 24 mo of administration in 8 cases. The nutritional condition and the hepatic functional reserve were compared between before and after the nizatidine treatment., Results: The result of a chewing gum test on the subjects before the administration of nizatidine showed that 50% produced less than 10 mL of saliva, i.e., the standard under which cases are considered to have hyposalivation. The results of these tests showed that the quantity of saliva secreted was 10.5 ± 6.8 mL before administration of nizatidine, 10.9 ± 6.0 mL after 6 mo, 10.6 ± 4.9 mL after 12 mo, and 11.8 ± 6.8 mL after 24 mo administration. Thus, there was a slowly increasing trend in the quantity of saliva in the whole group. The percentage of subjects with saliva production above 10 mL was 45.8% after 6 mo administration of nizatidine, that is, only a slight change from before its administration, but it was 64.3% after 12 mo, that is, a significant increase. The saliva secretion by subject patients was examined before the beginning of administration of nizatidine, 12 mo later, and 24 mo later, and Fisher's combined probability test was used to examine the results for increases in saliva secretion. The analysis yielded P values of 0.51 and 0.53 for 12 mo later and 24 mo later, respectively. Thus, although there was no statistically significant increase, it was confirmed that saliva secretion tended to increase. A VAS method was employed to study the intensities of subjective symptoms of oral dryness and eating difficulty. Almost every case indicated some improvement of subjective oral dryness on the VAS early in the administration, i.e., one month after. We also studied the effects of the administration of nizatidine on nutritional condition, hepatic functional reserve, and long-term prognosis of PBC. No significant improvements in cholinesterase (ChE) level, albumin (Alb) level, or Child-Pugh score were found during the period of observation from the beginning to the end of administration of nizatidine, nor in comparison with the non-administration group. A comparative analysis between before administration and 24 mo later yielded P values of 0.41 for Alb, 0.56 for ChE, and 0.59 for the Child-Pugh scores., Conclusion: It was confirmed that administering nizatidine to cases of PBC with dry mouth increased the secretion of saliva and improved the symptoms.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.